Artesunate/mefloquine

{{Short description|Antimalarial drug}}

{{Infobox drug

| drug_name =

| type = combo

| component1 = Artesunate

| class1 = artemisinin

| component2 = Mefloquine

| class2 = antimalarial

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_AU_comment =

| legal_CA =

| legal_UK =

| legal_US =

| legal_UN =

| legal_NZ =

| legal_status =

| routes_of_administration =

| CAS_number = 60473-87-2

| ATCvet =

| ATC_prefix = P01

| ATC_suffix = BF02

| PubChem =

| DrugBank =

}}

Artesunate/mefloquine is a medication used to treat malaria. It is a fixed dose combination of artesunate and mefloquine. Specifically it is recommended to treat uncomplicated falciparum malaria.{{cite book | vauthors = ((World Health Organization)) |title=The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, 2013 (including the 18th WHO Model List of Essential Medicines and the 4th WHO Model List of Essential Medicines for Children) |year=2014|publisher=World Health Organization|isbn=9789241209854|page=43–4|hdl=10665/112729 | hdl-access=free }} It is taken by mouth.

Side effects are similar to the medications being used separately. Use is recommended as it decreases the possibility of either medications being used alone. Dose forms appropriate for children are also available.

Artesunate/mefloquine came into commercial use in 2008.{{cite book| vauthors = Staines HM, Krishna S |author-link2=Sanjeev Krishna|title=Treatment and Prevention of Malaria: Antimalarial Drug Chemistry, Action and Use|date=2012|publisher=Springer Science & Business Media|isbn=9783034604802|page=239|url=https://books.google.com/books?id=IXWOXUpylO8C&pg=PA239|language=en|url-status=live|archive-url=https://web.archive.org/web/20161220161905/https://books.google.ca/books?id=IXWOXUpylO8C&pg=PA239|archive-date=2016-12-20}} It is on the World Health Organization's List of Essential Medicines.{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }} It is approved for medical use in Brazil, India, and Malaysia. It is not commercially available in the United States.{{cite book| vauthors = Sanford CA, Jong EC, Pottinger PS |title=The Travel and Tropical Medicine Manual|date=2016|publisher=Elsevier Health Sciences|isbn=9780323417426|page=307|edition=5|url=https://books.google.com/books?id=jyTRDAAAQBAJ&pg=PA307|language=en|url-status=live|archive-url=https://web.archive.org/web/20161220162041/https://books.google.ca/books?id=jyTRDAAAQBAJ&pg=PA307|archive-date=2016-12-20}}